arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Ovid Therapeutics Inc.

OVID
$2.62 ▼ -0.04 (-1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ovid Therapeutics Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 1181.3%
Op. Margin None
ROIC -32.5%
FCF / Share None
Trailing P/E
Price / Book 2.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.25M
↑ +1181.3%
Net Income Profit after all expenses
$-17.41M
↑ +34.1%
Operating Margin Operating profit as % of sales
-26.6%
↓ -144.6%
FCF / Share Free cash flow per share
$-0.65
↑ +19.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
31
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 43 quarters